PT Kimia Farma (Persero) Tbk (the Company) shows the results of the performance of the first half of 2016 were satisfactory.
This is evident from the total revenue in the first semester 2016 amounted to Rp 2.489 trillion, an increase of 18.07% compared to total revenue in the first half - in 2015 amounting to Rp 2.108 trillion. While the company's net profit rose 19.70% from 79.814 billion in the first half of 2015 to Rp 95.54 billion in the first half of 2016
The revenue growth was obtained from PT Kimia Farma Trading & Distribution (KFTD), a subsidiary engaged in the trading and distribution sector, which grew by 29.30%. For the performance of subsidiaries engaged in the retail sector and health services, namely PT Kimia Farma Apotek (KFA), revenue growth amounted to 14.64%. The performance of the subsidiaries involved in the manufacturing sector quinine products that most of its products exported to foreign countries, namely PT Sinkona Indonesia Lestari (SIL), a good contribution, with a growth in revenue of 27.06%.
To continue to improve the growth rate of the Company's performance, management has designed a grand strategy that is being built production facilities Factory Banjaran with a capacity of 4 (times) as much of the existing plant now, the construction of Salt Plant Pharmaceutical stage II with a capacity of 4000 tons which will be able to meet the raw material needs Pharmaceutical salts Indonesia of 6,000 tons / year, and will start the process of Ground Breaking mill PT Kimia Farma Sungwun Pharmacopia which is the first Drug Raw Materials factory in Indonesia.
The Company will conduct Rapid Building Ground Breaking Test, which is a medical equipment test kit for the detection of diseases such as HIV, syphilis, malaria and hepatitis. For the next stage will be developed for drug test kit and dengue fever. Until June 2016, the Company's network of health services has reached 770 outlets pharmacies, 347 health centers and 43 clinics laboratories scattered throughout Indonesia.
The Company is targeting to expand the network of health services each year a number of at least 100 pharmacy outlets, 50 health clinics and five clinical laboratories. The expansion is also demonstrated by the implementation of the MoU between the Company and DWAA LTD CO, company health networks in Saudi Arabia, in the framework of plans to acquire some shares of DWAA LTD CO, which has 30 health network (pharmacies, clinics and clinical laboratories) in Saudi Arabia. Later the Company may serve pilgrims and Umrah Indonesia as well sebagaistep-stone for the expanded distribution of the Company's products to the international market.
In the optimization of the asset, the Company continues to make efforts to optimize the company's assets by cooperating with strategic partners who are competent and experienced. As the construction Moxy Dago Hotel in Bandung, Hotel in Matraman Jakarta Development and Construction of Hospital in Saharjo Jakarta, with cooperation Build Operate Transfer (BOT).